Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 28.33% is in line with its 5-year average of 26.67%, around the middle of its 5-year range (7.41%–46.48%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.39% below its 12-month average of 37.47%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 28.33%.
DEBT TO ASSETS RATIO
28.33%
DEBT TO ASSETS RATIO AVG TTM
37.47%
DEBT TO ASSETS RATIO AVG 3Y
32.92%
DEBT TO ASSETS RATIO AVG 5Y
26.67%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-24.39%
CURRENT VS 3Y AVG
-13.93%
CURRENT VS 5Y AVG
+6.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 866 covered companies
CURRENT VS SECTOR MEDIAN
+31379.74%
vs the sector median at left
MeiraGTx Holdings plc
Market Cap
$984.90M
Debt to Assets Ratio
28.33%
TTM Avg
37.47%
3Y Avg
32.92%
5Y Avg
26.67%
Market Cap
$984.29M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.09M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$990.12M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$976.29M
Debt to Assets Ratio
0.33%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$970.36M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $984.90M | 28.33% | 37.47% | 32.92% | 26.67% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $984.29M | 0.16% | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $981.09M | 0.01% | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $990.12M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | 0.33% | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $997.29M | 0.01% | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $970.36M | 0.02% | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | 0.01% | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $953.94M | 0.16% | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 0.54% | N/A | N/A | N/A |
Debt/Assets
28.3%
Debt/Equity
0.52
Current Ratio
3.76
Interest Coverage
-8.7x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 28.33% |
| 2026-03-31 | 35.78% |
| 2025-12-31 | 36.28% |
| 2025-09-30 | 46.48% |
| 2025-06-30 | 40.49% |
| 2025-03-31 | 36.10% |
| 2024-12-31 | 31.44% |
| 2024-09-30 | 28.96% |
| 2024-06-30 | 32.84% |
| 2024-03-31 | 28.58% |
| 2023-12-31 | 19.48% |
| 2023-09-30 | 33.76% |
| 2023-06-30 | 29.40% |
| 2023-03-31 | 31.85% |
| 2022-12-31 | 28.99% |
| 2022-09-30 | 30.51% |
| 2022-06-30 | 8.99% |
| 2022-03-31 | 8.48% |
| 2021-12-31 | 7.41% |
| 2021-09-30 | 8.09% |
| 2021-06-30 | 7.81% |
| 2021-03-31 | 6.70% |
| 2020-12-31 | 6.12% |
| 2020-09-30 | 6.57% |
| 2020-06-30 | 7.12% |
| 2020-03-31 | 6.94% |
| 2019-12-31 | 7.16% |
| 2019-09-30 | 7.12% |
| 2019-06-30 | 6.74% |
| 2019-03-31 | 1.39% |
| 2018-12-31 | 0.04% |
| 2018-09-30 | 0.04% |
| 2018-06-30 | 0.04% |
| 2018-03-31 | 0.11% |
| 2017-12-31 | 5.83% |
